Randomized study comparing efficacy/toxicity of monotherapy trastuzumab followed by monotherapy docetaxel at progression, and combination trastuzumab/docetaxel as first-line chemotherapy in HER2-neu positive, metastatic breast cancer (MBC) (HERTAX study)

被引：8

作者：

Bontenbal, M.

Seynaeve, C.

Stouthard, J.

Bos, M.

Braun, H.

Erdkamp, F. L.

van Deijk, G.

Schmitz, P.

Van der Stelt-Frissen, I.

Hamberg, P.

Klijn, J.

机构：

[1] Dr Daniel Den Hoed Canc Ctr, Erasmus MC, NL-3008 AE Rotterdam, Netherlands

[2] MCRZ, Rotterdam, Netherlands

[3] Reinier de Graaf Hosp, Delft, Netherlands

[4] Vlietland Hosp, Schiedam, Netherlands

[5] Maasland Hosp, Sittard, Netherlands

[6] Haga Hosp, The Hague, Netherlands

来源：

关键词：

D O I：

10.1200/jco.2008.26.15_suppl.1014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1014

引用

页数：1